Clinical Trial Update: A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy of Sage-217 in adults with major depressive disorder completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2023-12-05